13 reports of this reaction
1.8% of all ACETAMINOPHEN, CAFFEINE, PYRILAMINE MALEATE reports
#9 most reported adverse reaction
INSOMNIA is the #9 most commonly reported adverse reaction for ACETAMINOPHEN, CAFFEINE, PYRILAMINE MALEATE, manufactured by OPMX LLC. There are 13 FDA adverse event reports linking ACETAMINOPHEN, CAFFEINE, PYRILAMINE MALEATE to INSOMNIA. This represents approximately 1.8% of all 712 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, CAFFEINE, PYRILAMINE MALEATE who experience insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INSOMNIA is a less commonly reported adverse event for ACETAMINOPHEN, CAFFEINE, PYRILAMINE MALEATE, but still significant enough to appear in the safety profile.
In addition to insomnia, the following adverse reactions have been reported for ACETAMINOPHEN, CAFFEINE, PYRILAMINE MALEATE:
The following drugs have also been linked to insomnia in FDA adverse event reports:
INSOMNIA has been reported as an adverse event in 13 FDA reports for ACETAMINOPHEN, CAFFEINE, PYRILAMINE MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INSOMNIA accounts for approximately 1.8% of all adverse event reports for ACETAMINOPHEN, CAFFEINE, PYRILAMINE MALEATE, making it a notable side effect.
If you experience insomnia while taking ACETAMINOPHEN, CAFFEINE, PYRILAMINE MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.